Concord Biotech Limited (BOM:543960)
India · Delayed Price · Currency is INR | Market Cap | 125.70B -20.2% |
| Revenue (ttm) | 10.55B -12.1% |
| Net Income | 2.61B -29.8% |
| EPS | 24.78 -30.2% |
| Shares Out | n/a |
| PE Ratio | 48.18 |
| Forward PE | 38.07 |
| Dividend | 18.25 (1.52%) |
| Ex-Dividend Date | Jul 24, 2026 |
| Volume | 354,664 |
| Open | 1,235.00 |
| Previous Close | 1,166.80 |
| Day's Range | 1,188.75 - 1,272.75 |
| 52-Week Range | 987.05 - 2,149.90 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 1,196.00 (-0.35%) |
| Earnings Date | May 29, 2026 |
About Concord Biotech
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin,... [Read more]
Financial Performance
In fiscal year 2026, Concord Biotech's revenue was 10.55 billion, a decrease of -12.10% compared to the previous year's 12.00 billion. Earnings were 2.61 billion, a decrease of -29.80%.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for 543960 stock is "Buy." The 12-month stock price target is ₹1,196, which is a decrease of -0.35% from the latest price.
News
Concord Biotech Transcript: Q4 25/26
FY 2026 saw a 12% revenue decline due to geopolitical and supply chain disruptions, but profitability remained resilient with a 35% EBITDA margin. Management expects FY 2027 growth to exceed historical rates, supported by new facilities, regulatory approvals, and operating leverage.
Concord Biotech Quarterly report: Q4 2026
Concord Biotech has published its Q4 2026 quarterly earnings report on June 1, 2026.
Concord Biotech Slides: Q4 2026
Concord Biotech has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on June 1, 2026.
Concord Biotech Transcript: Q3 25/26
Q3 FY26 saw 14% revenue growth year-over-year, with API volumes driving performance and injectables poised for future growth. Margins were impacted by startup costs, but normalization is expected as new facilities scale. Cash position remains strong, supporting both organic and inorganic expansion.
Concord Biotech Quarterly report: Q3 2026
Concord Biotech has published its Q3 2026 quarterly earnings report on February 12, 2026.
Concord Biotech Slides: Q3 2026
Concord Biotech has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on February 12, 2026.
Concord Biotech Transcript: Q2 25/26
Q2 FY2026 saw a 20% YoY revenue decline due to regulatory and geopolitical delays, but management expects a strong H2 recovery as deferred sales resume. Margins remain robust, with new facilities and product launches set to drive future growth.
Concord Biotech Quarterly report: Q2 2026
Concord Biotech has published its Q2 2026 quarterly earnings report on November 14, 2025.
Concord Biotech Slides: Q2 2026
Concord Biotech has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on November 14, 2025.
Concord Biotech Transcript: Q1 25/26
Q1 FY26 revenue declined 5% year-over-year to INR 204 crore due to sales lumpiness, with EBITDA and PAT impacted by startup costs at the new injectable facility. Formulation revenue grew 12%, API declined 10%, and the company advanced its US and India market presence, CDMO, and injectables ramp-up.
Concord Biotech Quarterly report: Q1 2026
Concord Biotech has published its Q1 2026 quarterly earnings report on August 11, 2025.
Concord Biotech Slides: Q1 2026
Concord Biotech has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on August 11, 2025.